Sponsor
Harada KI et al. – Despite the significant induction of γ–butyrolactone (GBL), adjuvant uracil/tegafur (UFT) therapy failed to show a preventive effect on intravesical recurrence of non–muscle invasive urothelial carcinoma of the bladder. Therefore, the authors should consider enhancing the anti–angiogenic effect of GBL using an alternative administration schedule of UFT.
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor